Chapter 22. Dyslipidemia Medication Therapy Management Data Set
Which of the following lipid markers remains valid if the patient is not fasting at the time the lipid panel is completed?
Each of the following is considered a CHD risk equivalent EXCEPT:
a. Congestive heart failure
c. Abdominal aortic aneurysm
d. Peripheral arterial disease
Which of the following LDL goals is appropriate for a patient diagnosed with type 2 diabetes mellitus?
Which of the following would best describe rhabdomyolysis in living room language?
a. A serious degradation of muscle tissue caused by statins. It is associated with myalgias and myoglobinuria.
b. A severe condition where the muscles are breaking down. This presents with muscle weakness and pain, along with cola-colored urine.
c. A potential side effect of HMG-CoA reductase inhibitors. The patient may experience muscle pain (myalgia), weakness, or cramps.
d. Something bad that happens, a bad reaction, or an unexplained or unwanted effect.
JJ is a 42-year-old man with dyslipidemia who is new to your MTM service. After completing a medication therapy review with JJ, you complete a MAP. Which of the following statements best represents the type of information you should include in JJ's MAP?
a. Simvastatin 20 mg tablet: take nightly for cholesterol
b. Side effects you may experience with this medication include myalgias, myopathy, and rhabdomyolysis
c. Remember to take your simvastatin every night; try using a pillbox or alarm reminder to help you remember
d. The pharmacist will call your doctor to discuss switching your simvastatin to a stronger medication for your high cholesterol
All of the following would indicate the need for referral to the emergency department EXCEPT: